Brief Title
Apathy in Tourette Syndrome and Changes in Quality of Life
Official Title
Apathy in Tourette Syndrome and Changes in Quality of Life - Effect of Medications
Brief Summary
Tourette syndrome is a complex neuropsychological disorder with both motor and vocal tics associated with multiple psychological co-morbidities. Apathy has not been widely studied in patients with Tourette syndrome. Apathy can result in decrease in self-care and disease control. In this study investigators will compare the occurrence of apathy in the adolescent Tourette syndrome population (at the UF center for movement disorders and Neurorestoration) to an age and gender matched control population. Investigators will also assess the role of commonly used medications in the Tourette population (neuroleptics and selective serotonin receptor inhibitors) in the occurrence of apathy.
Detailed Description
Tourette syndrome(TS) is a complex neuropsychological disorder with both motor and vocal tics associated with multiple psychological co-morbidities. The most common co-morbidities include obsessive compulsive disorder (OCD), attention deficit and hyperactivity disorder (ADHD) and depression. Apathy has not been extensively studied in the Tourette syndrome population. Apathy is currently defined as reduced motivation, with symptoms in at least two of three domains of reduced initiative, reduced interest and/or reduced emotional responsiveness. A study assessed the prevalence of apathy in multiple movement disorders and reported that apathy is much more common in disorders associated with slowed movements like Parkinson disease while less common in disorders with increased movements like Huntington disease and Tourette syndrome in adults. However, no apathy studies in adolescent patients with Tourette syndrome are published. Disengagement from treatment may affect health outcomes in other disease states. Apathy has significant effects on the quality of life and health outcomes in many patients. Apathy can be a direct manifestation of the neuropsychological process (intrinsic to the disease) or can be secondary to medication side effects most notably anti-dopaminergic agents and some reports of selective serotonin receptor inhibitors (SSRI). Further attention to the prevalence and impact of apathy in the adolescent Tourette syndrome population is needed to explore if this may be a factor influencing TS management and ultimately Quality of life (QOL). Multiple psychotropic medications are used in the management of tics as well as the psychological co-morbidities. How these medications affect apathy prevalence in Tourette syndrome patients is not known.
Study Type
Observational
Primary Outcome
Children's Motivation Scale
Secondary Outcome
Yale Global Tic Severity Scale (YGTSS)
Condition
Tourette Syndrome
Intervention
Children's Motivation Scale
Study Arms / Comparison Groups
Patients with Tourette Syndrome
Description: The primary caregiver will be asked to fill the Children's motivation Scale. Other measures will be collected including a clinician filled Yale Global Tic Severity Scale (YGTSS) - severity score, Center for Epidemiological Studies Depression Scale for Children (CES-DC) and Gilles de la Tourette Syndrome Quality Of Life scale (GTS-QOL). Demographic data will also be collected for each study patient. Demographic data will also be collected for each study patient.
Publications
* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.
Recruitment Information
Recruitment Status
Other
Estimated Enrollment
38
Start Date
April 2016
Completion Date
April 2017
Primary Completion Date
March 2017
Eligibility Criteria
Inclusion Criteria: - Diagnosis: Tourette syndrome - Age: 12-16 years - Followed at the CMDNR Exclusion Criteria: - History of cerebral palsy or traumatic brain injury
Gender
All
Ages
12 Years - 16 Years
Accepts Healthy Volunteers
No
Contacts
Wissam Deeb, ,
Location Countries
United States
Location Countries
United States
Administrative Informations
NCT ID
NCT02765178
Organization ID
IRB201500989
Responsible Party
Sponsor
Study Sponsor
University of Florida
Study Sponsor
Wissam Deeb, Principal Investigator, UF Center for Movement Disorders and Neurorestoration
Verification Date
July 2017